• CG Oncology posted a net loss of USD 79.1 million, or USD 0.90 per share, for Q2 2026.
• R&D expense climbed to USD 54.7 million from USD 31.3 million a year earlier, due to higher clinical trial and CMC costs and higher headcount.
• G&A expense rose to USD 29.0 million from USD 17.4 million, driven by higher personnel costs from increased headcount.
• Cash, cash equivalents and marketable securities totaled USD 1.0 billion at June 30, down from USD 1.1 billion at March 31; funding runway through 2029.
• Phase 3 PIVOT-006 topline data are expected in the near term; BLA completion targeted for Q4 2026 for HR BCG-unresponsive NMIBC with CIS.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CG Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-336886), on August 06, 2026, and is solely responsible for the information contained therein.